RxDoctor Payments Data

Katie Greiner

Optometrist · Kent, OHNPI 1972732436

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 63.2% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2022 at $29,301 and has fallen 61.1% since, to $11,384 in 2025. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,968in general payments, 2019–2025

Across 398 payments — averaging $163.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Alcon$9K
  • Glaukos Corporation$4K
  • Johnson & Johnson Vision Care, Inc.$2K
  • Coopervision Inc.$1K
  • Biotissue Holdings Inc.$1K
  • plus $6K from 28 others

What the payments were for

  • Consulting fees$8,28313%
  • Speaking & faculty fees$34,38753%
  • Travel & lodging$9,66515%
  • Food & beverage$12,24519%
  • Education$180%
  • Gifts$3701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,968 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$47,516
Medicare patients
210
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$55,837
XiidraLifitegrast17$16,999
LumiganBimatoprost30$16,987
Cyclosporine15$6,661
RocklatanNetarsudil Mesylat/Latanoprost11$5,577
TafluprostTafluprost/Pf18$2,486
Doxycycline Hyclate24$1,396
Prednisolone Acetate26$1,367
Bimatoprost14$1,361
Latanoprost72$1,035
Fluorometholone14$972
ErythromycinErythromycin Base45$695
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$654
Timolol Maleate70$595
Dorzolamide Hcl47$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$41,061$72,82469 claims
Bausch & Lomb Americas Inc.Xiidra$790$16,99917 claims
Aerie Pharmaceuticals, Inc.Rocklatan$130$5,57711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Kent

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →